FOR PHARMACISTS · SCIENTIFIC COLLECTION 10.0310 monographs · 36 SOPs · 22 forms
Sikaliascompounding.grSikalias Greek Formulary
Home / Monographs / Emulsifying Wax · CGR-BP-015

CGR-BP-015 / EDITION 10.0

Emulsifying Wax

Emulsifying wax · United Kingdom · BP

2026-10-14Purchased-material specification

Collection and scientific editing: Stasinos Chr. SikaliasContent edition: 10.0Record editorial review date: 2026-10-14

Download bilingual PDFJSON

Final editorial decision

Preferred implementation route: obtain pharmacopoeial anionic emulsifying wax from an approved supplier, with documented type and composition match to the cited BP material. Accept the actual lot only with its CoA, identity/quality checks, storage instructions and valid expiry or justified retest date. Nonionic NF wax and cetomacrogol wax are not interchangeable. For purchased material use the approved supplier dating and after-opening conditions; do not invent a compounded-preparation BUD. Retain the historical preparation method as a reference. No numerical dating is established here for in-house production: the 4 mL process-water input and residual-water specification are not aw measurements.

Required evidence

  • Approved pharmaceutical material specification: anionic cetostearyl-alcohol/sodium-lauryl-sulfate wax, matched in type, composition and functionality to the cited BP material.
  • Actual lot CoA, incoming identity/quality acceptance, supplier traceability, expiry or justified retest date, storage/after-opening conditions and SDS.
  • Alternatively, for in-house manufacture: real batch record, specification compliance and aw-category evidence for representative finished wax using a suitable method.

Closure criteria

  • Close the research decision by specifying procurement of the correct pharmacopoeial grade. Supplier examples establish availability, not acceptance of an actual lot.
  • Complete routine purchased-lot acceptance against the approved specification, CoA and identity/quality checks. Nonionic NF wax or cetomacrogol wax is not an automatic substitute.
  • For in-house manufacture, residual water and cessation of frothing do not establish the aw category. Use suitable finished-matrix evidence with a decision rule accounting for measurement uncertainty.

Scope

Final editorial decision dated 14 October 2026. This is not a certificate of laboratory results or actual batch release.

Sources and references

  1. USP General Chapter <795> FAQs, November 1 2023Questions 52, 60, 61, 62, 63; printed pp.11,14
  2. VVF manufacturer: Emulsifying WaxesProduct table: Vegarol EW 200; compare EW 100 and EW 300
  3. Croda Pharma manufacturer: Crodex A pharmaProduct description and pharmacopoeia compliance
  4. British Pharmacopoeia: Content Usage Licence for Individual UsersSections1,4 and5

REFERENCE FORMULA

Reference formula

Reference basis: 100 g ξηρών συστατικών / dry inputs

IngredientSource quantityScaled quantity
Cetostearyl alcohol90 g—
Sodium lauryl sulfate10 g—
Purified water4 (process input) mL—

Prerequisite formulations

No separate prerequisite monograph is listed.

Documentation

Preparation description
Emulsifying wax: Emulsifying Wax. Additional appearance criteria are not established by the specific text reviewed. [1]
Action and use
Pharmaceutical base or excipient for incorporation into an appropriate preparation. Compatibility with each active requires separate assessment. [1]
Specifications
Composition and final quantity follow the formula table (100 g ξηρών συστατικών / dry inputs). The reviewed specific text gives no numerical assay, microbial-count or physicochemical acceptance range; no unsupported limit is assigned. [1]
Light
Finished-product photostability is not specified. Any required container light protection is stated under Storage. [1]
Air and oxidation
No oxidative stability study of the finished mixture or inert-atmosphere requirement is provided. Use the source container. [1]
Water and solubility
No quantitative hydrolytic stability limit is given for this formula. Retain the prescribed water amount and quality. [1]
Humidity
No numerical relative-humidity limit is given for the finished product. Prevent raw-material wetting and condensation entering the container. [1]
Temperature
No permitted temperature excursion or freeze–thaw cycle is established. Processing and storage temperatures are stated in their respective fields. [1]
pH and compatibility
No pH is assigned to the dry dosage form. Any analytical-extract pH requires the specified method. [1]
Other interactions
No complete compatibility test with added actives or alternative excipients is provided. Substitutions require separate evidence. [1]
Ingredient-specific information
Sodium lauryl sulfate: JP describes a clear or opalescent solution of 1 g in 10 mL water. [3]
Staff protection
Clean long-sleeved laboratory clothing, hair covering and gloves during handling; change gloves after contamination or damage. [1], [2], [4]
Risk assessment
Reference batch: 100 g ξηρών συστατικών / dry inputs. First ingredient: Cetostearyl alcohol, 90 g. Independently check chemical form, units and every scale conversion before weighing.
As an intermediate, label identity and strength clearly and do not dispense as a finished medicine. Dilution or addition of an active requires new excipient, preservation and BUD calculations. Confirm release of every required base.
For the local assessment record quantity per preparation, work frequency, duration of open handling, potential exposure routes and effectiveness of controls. These are assessment inputs; no fictitious final risk score is assigned.
For this procedure’s heating stage, check thermometer, heating method, duration and prevention of overheating/solvent loss. Completion of mixing does not establish cooling or complete homogenisation.
Release checkpoint: confirm final volume or mass at the reference temperature, intended clarity or dispersion, and specified container/closure. Do not equate grams and millilitres without a justified density.
Contains cetostearyl or cetyl alcohol, which can cause local skin reactions; include components of the selected base in the assessment. [1], [7], [9], [12]
Compounding conditions
Before mixing: verify each ingredient’s chemical form and lot, record theoretical amounts and check equipment cleanliness. Follow the temperatures and addition sequence in the procedure below. [1], [4]
BUD rationale
Preferred implementation route: obtain pharmacopoeial anionic emulsifying wax from an approved supplier, with documented type and composition match to the cited BP material. Accept the actual lot only with its CoA, identity/quality checks, storage instructions and valid expiry or justified retest date. Nonionic NF wax and cetomacrogol wax are not interchangeable. For purchased material use the approved supplier dating and after-opening conditions; do not invent a compounded-preparation BUD. Retain the historical preparation method as a reference. No numerical dating is established here for in-house production: the 4 mL process-water input and residual-water specification are not aw measurements. [11], [13], [14], [15]
Prerequisites
No separately registered base is required. Any commercial vehicle remains the exact named product in the formula table. [1]
Equipment
Balance with suitable minimum weight, mortar/pestle or homogeniser, mixing vessels, spatulas, thermometer for heated processes and volumetric equipment for mL quantities. [1]
Compounding method
Historical source method; this edition does not approve in-house manufacture. The implementation route is procurement of the defined pharmacopoeial material.

Melt cetostearyl alcohol at about 95 °C. Add sodium lauryl sulfate and water. Heat to 115 °C with vigorous stirring until frothing ceases and the product becomes translucent. Cool rapidly. [1]
Observations
The 4 mL water is a process addition. Record actual yield; do not assume a final mass of 104 g.
Measure finished wax after cooling and equilibration with a matrix-suitable method. Link to raw-material lots, residual moisture and packaging. For this edition’s conservative low-aw decision, the highest result plus uncertainty must be <0.60; this uncertainty rule is editorial policy, not a verbatim USP criterion.
Practical evidence route: assess a representative finished batch or suitable product-specific evidence for the exact composition/process. Alternatively, a supplied BP wax may be qualified through its specification, CoA, lot and suitability; this does not validate local synthesis of this printed formula. Repeating aw independently for every unchanged, documented batch is not automatically required. [1], [9], [10]
Container and packaging
Selection for local assessment: well-closed dry container suitable for the dosage form. Check cleanliness, integrity, closure and material compatibility before filling. The specific monograph does not validate a particular commercial container. [1]
Quality control
The specific monograph supplies no separate assay. Check starting-material identity/quality and the general pharmacopoeial dosage-form requirements referenced by the source.
Record the method, acceptance criterion, actual result and reviewer separately in F-005. A critical specification failure requires quarantine and investigation under SOP-015; retesting needs justification. [1], [9]
Storage

For a general-rule duration, also apply the temperature of the selected BUD category. The source does not support arbitrary temperature changes. [5]
Dispensing
This entry does not generate a label or authorise patient dispensing. Consult its final decision and implementation criteria. [11], [13], [14], [15]
Labelling
No dispensing label is issued by this entry. [11], [13], [14], [15]
final_decision
Preferred implementation route: obtain pharmacopoeial anionic emulsifying wax from an approved supplier, with documented type and composition match to the cited BP material. Accept the actual lot only with its CoA, identity/quality checks, storage instructions and valid expiry or justified retest date. Nonionic NF wax and cetomacrogol wax are not interchangeable. For purchased material use the approved supplier dating and after-opening conditions; do not invent a compounded-preparation BUD. Retain the historical preparation method as a reference. No numerical dating is established here for in-house production: the 4 mL process-water input and residual-water specification are not aw measurements. [11], [13], [14], [15]

Independent Greek/English adaptation and organisation of facts from the cited source. This is not an official translation or publisher endorsement.

Sources and references

  1. British Pharmacopoeia 2016 — Emulsifying Wax2016PDF pp. 1–2; user-supplied BP extract; URL is publisher catalogue, not the licensed full monographmaster formula2026-09-10
  2. PN/L/PG/002/00 INDUMENTARIAΔιαθέσιμο κείμενο / Retrieved textPDF pp. 1–5general staff protection2026-09-10
  3. MHLW — Japanese Pharmacopoeia XVIII: Sodium Lauryl SulfateJP XVIII, 2021; English textPrinted p. 1718; Description; Containers and storageraw-material monograph2026-09-12
  4. ASHP — USP <795> Key Changes2023pp. 1–3: scope, water activity and staff precautionsprofessional guidance; not the licensed USP chapter2026-09-12
  5. Texas State Board of Pharmacy — adopted 22 TAC §291.131, nonsterile compoundingTexas Register, 7 June 2024Beyond-use dating: aw categories, 14/35/90/180 days, limits and extensionspublic regulatory implementation of USP <795> BUD framework; not Greek law2026-09-12
  6. Illinois IDFPR — Nonsterile Compounding Self-Inspection ReportPublic checklist, retrieved 12 September 2026pp. 15–16, Establishing beyond-use datesPublic regulatory implementation of USP <795>; not Greek law; general limits and requirements for extension2026-09-12
  7. NIOSH — Managing Hazardous Drug Exposures: Information for Healthcare Settings2023; DHHS (NIOSH) 2023-130Risk assessment; printed pp. 27–33, activity/formulation control tableWorkplace exposure, hierarchy of controls and activity-specific PPE; US government public-domain document2026-09-12
  8. USP — Compounding Standards and Beyond-Use Dates, 2022 updateNovember 2022, published by USP; public copy hosted by Mississippi Boardpp. 1–2; nonsterile tableRisk-based default categories; not product-specific stability or Greek law2026-09-12
  9. PIC/S — Guide to Good Practices for the Preparation of Medicinal Products in Healthcare EstablishmentsPE 010-4, 1 March 2014Chapters 1–9; Annex 2 (nonsterile liquids, creams, ointments)Professional quality-system framework; not automatic national legal adoption or certification2026-09-12
  10. FDA — Water Activity (aw) in FoodsInspection Technical Guide 39, 16 April 1984; website copy accessed 2026-09-12Definition; sorption behaviour; measurement equipmentMetrological principles only. Food regulatory thresholds and old instrument recommendations are not pharmaceutical BUD rules2026-09-12
  11. USP — General Chapter <795> FAQsUpdated 1 November 2023Questions 52, 54–56, 60–62; PDF pp. 11–14Primary clarification of aw classification, extension prerequisites and compounded-component BUDs; not automatic Greek legal adoption2026-10-14
  12. EMA — Excipients in the labelling and package leaflet, Annex Revision 5Published 5 December 2025EN and EL worksheets: arachis oil, wool fat, cetostearyl/cetyl alcohol, chlorocresolCurrent primary excipient warnings; used as a scientific labelling reference, without claiming MAH obligations automatically apply to a compounded prescription2026-10-14
  13. VVF manufacturer: Emulsifying WaxesProduct table: Vegarol EW 200; compare EW 100 and EW 300Targeted prerequisite / publication decision; not batch result2026-10-14
  14. Croda Pharma manufacturer: Crodex A pharmaProduct description and pharmacopoeia complianceTargeted prerequisite / publication decision; not batch result2026-10-14
  15. British Pharmacopoeia: Content Usage Licence for Individual UsersSections1,4 and5Targeted prerequisite / publication decision; not batch result2026-10-14